Cancer narratives: words beyond disease—a call for submissions

Por Rayson, D.
Publicado em 2013

The cost–utility of adjuvant chemotherapy using docetaxel and cyclophosphamide compared with doxorubicin and cyclophosphamide in breast cancer

Por Younis, T., Rayson, D., Skedgel, C.
Publicado em 2011

Reflecting on inpatient palliative chemotherapy—is there ever a “right place” at the “right time”?

Por Rayson, D., Kain, D.A.
Publicado em 2014

Wait times for breast cancer care

Por Saint-Jacques, N, Younis, T, Dewar, R, Rayson, D
Publicado em 2007

Chemotherapy uptake and wait times in early-stage non-small-cell lung cancer

Por Gray, S., Bu, J., Saint-Jacques, N., Rayson, D., Younis, T.
Publicado em 2012

Cost–utility of adjuvant zoledronic acid in patients with breast cancer and low estrogen levels

Por Lamond, N.W.D., Skedgel, C., Rayson, D., Younis, T.
Publicado no Curr Oncol (2015)

Canadian supportive care recommendations for the management of anemia in patients with cancer

Por Mikhael, J., Melosky, B., Cripps, C., Rayson, D., Kouroukis, C.T.
Publicado em 2007

The cost burden of trastuzumab and bevacizumab therapy for solid tumours in Canada

Por Drucker, A., Skedgel, C., Virik, K., Rayson, D., Sellon, M., Younis, T.
Publicado em 2008

Management of skin rash during egfr-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations

Por Melosky, B., Burkes, R., Rayson, D., Alcindor, T., Shear, N., Lacouture, M.
Publicado em 2009

Inter-institutional pathology consultations for breast cancer: impact on clinical oncology therapy recommendations

Por Price, J.A., Grunfeld, E., Barnes, P.J., Rheaume, D.E., Rayson, D.
Publicado em 2010

Incidence of febrile neutropenia during adjuvant chemotherapy for breast cancer: a prospective study

Por Rayson, D., Lutes, S., Sellon, M., Colwell, B., Dorreen, M., Drucker, A., Jeyakumar, A., Snow, S., Younis, T.
Publicado em 2012

Endocrine therapy for postmenopausal women with hormone receptor–positive her2–negative advanced breast cancer after progression or recurrence on nonsteroidal aromatase inhibitor t...

Por Pritchard, K.I., Gelmon, K.A., Rayson, D., Provencher, L., Webster, M., McLeod, D., Verma, S.
Publicado em 2013

Developing a prediction model for benefit from fulvestrant in heavily pretreated metastatic breast cancer patients

Por Amir, E, Freedman, OC, Chia, S, Petrella, T, Dent, S, Tonkin, K, Ahmad, I, Rayson, D, Dranitsaris, G, Clemons, M
Publicado no Breast Cancer Res (2009)

Novel agents and associated toxicities of inhibitors of the pi3k/Akt/mtor pathway for the treatment of breast cancer

Por Chia, S., Gandhi, S., Joy, A.A., Edwards, S., Gorr, M., Hopkins, S., Kondejewski, J., Ayoub, J.P., Califaretti, N., Rayson, D., Dent, S.F.
Publicado no Curr Oncol (2015)

The role of her2-targeted therapies in women with her2-overexpressing metastatic breast cancer

Por Dent, S., Verma, Sh., Latreille, J., Rayson, D., Clemons, M., Mackey, J., Verma, Su., Lemieux, J., Provencher, L., Chia, S., Wang, B., Pritchard, K.
Publicado em 2009

The role of neoadjuvant her2-targeted therapies in her2-overexpressing breast cancers

Por Lemieux, J., Clemons, M., Provencher, L., Dent, S., Latreille, J., Mackey, J., Pritchard, K.I., Rayson, D., Verma, Sh., Verma, Su., Wang, B., Chia, S.
Publicado em 2009

Optimizing the management of her2-positive early breast cancer: the clinical reality

Por Verma, Su., Lavasani, S., Mackey, J., Pritchard, K., Clemons, M., Dent, S., Latreille, J., Lemieux, J., Provencher, L., Verma, Sh., Chia, S., Wang, B., Rayson, D.
Publicado em 2010

Guidelines for the diagnosis and management of carcinoid tumours. Part 1: The gastrointestinal tract. A statement from a Canadian National Carcinoid Expert Group

Por Maroun, J., Kocha, W., Kvols, L., Bjarnason, G., Chen, E., Germond, C., Hanna, S., Poitras, P., Rayson, D., Reid, R., Rivera, J., Roy, A., Shah, A., Sideris, L., Siu, L., Wong, R.
Publicado em 2006